Silverback Therapeutics/$SPRY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Silverback Therapeutics
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
Ticker
$SPRY
Sector
Primary listing
Employees
165
Headquarters
Website
SPRY Metrics
BasicAdvanced
$1B
-
-$0.49
0.96
-
Price and volume
Market cap
$1B
Beta
0.96
52-week high
$18.90
52-week low
$9.97
Average daily volume
2.6M
Financial strength
Current ratio
6.172
Quick ratio
5.838
Long term debt to equity
37.973
Total debt to equity
38.28
Profitability
EBITDA (TTM)
-58.733
Gross margin (TTM)
80.87%
Net profit margin (TTM)
-42.74%
Operating margin (TTM)
-52.82%
Effective tax rate (TTM)
-0.60%
Revenue per employee (TTM)
$680,000
Management effectiveness
Return on assets (TTM)
-13.85%
Return on equity (TTM)
-23.56%
Valuation
Price to revenue (TTM)
8.829
Price to book
5.21
Price to tangible book (TTM)
5.59
Price to free cash flow (TTM)
-16.291
Free cash flow yield (TTM)
-6.14%
Free cash flow per share (TTM)
-0.623
Growth
Revenue change (TTM)
22,367.80%
Earnings per share change (TTM)
5.48%
3-year revenue growth (CAGR)
259.94%
3-year earnings per share growth (CAGR)
-13.52%
What the Analysts think about SPRY
Analyst ratings (Buy, Hold, Sell) for Silverback Therapeutics stock.
Bulls say / Bears say
Generated $15.7 million in total revenue in Q2 2025, with $12.8 million from neffy U.S. net product sales, showing growing commercial momentum after launch (GlobeNewswire).
Achieved 93% commercial coverage in the U.S. with simplified prior authorization and a 52% gross-to-net retention rate, reducing hurdles for neffy prescriptions (GlobeNewswire).
Strengthened global presence with EURneffy approval in the U.K. and successful launch in Germany, marking the first international sales of the company’s needle-free epinephrine solution (GlobeNewswire).
Reported a net loss of $44.9 million in Q2 2025, driven by $54.3 million in SG&A expenses, highlighting substantial cash burn related to commercialization activities (GlobeNewswire).
Cash position fell from $275.7 million as of March 31, 2025 to $240.1 million at June 30, 2025, indicating a $35.6 million cash burn for the quarter, which could shorten the company’s cash runway (GlobeNewswire).
Neffy remains the only approved product so far; depending on a single product increases the company’s regulatory and commercial risk, especially if demand slows or competitors release new epinephrine delivery options (GlobeNewswire).
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2025.
SPRY Financial Performance
Revenues and expenses
SPRY Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Silverback Therapeutics stock?
Silverback Therapeutics (SPRY) has a market cap of $1B as of September 15, 2025.
What is the P/E ratio for Silverback Therapeutics stock?
The price to earnings (P/E) ratio for Silverback Therapeutics (SPRY) stock is 0 as of September 15, 2025.
Does Silverback Therapeutics stock pay dividends?
No, Silverback Therapeutics (SPRY) stock does not pay dividends to its shareholders as of September 15, 2025.
When is the next Silverback Therapeutics dividend payment date?
Silverback Therapeutics (SPRY) stock does not pay dividends to its shareholders.
What is the beta indicator for Silverback Therapeutics?
Silverback Therapeutics (SPRY) has a beta rating of 0.96. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.